一、本次交易标的资产过户情况 （一）资产交割及过户情况 本次交易的标的资产为澎立生物 100%股份，2026 年 1 月 14 日，公司收到 澎立生物出具的由其盖章证明标的股权已完成过户的《股东名册》。鉴于澎立生 物的公司性质为股份有限公司，根据相关法律法规的规定，股东名册更新完成即 表明资产过户程序已经完成。 证券代码：688293 证券简称：奥浦迈 公告编号：2026-007 上海奥浦迈生物科技股份有限公司 关于发行股份及支付现金购买资产并募集配套资金 之标的资产过户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"上市公司"）拟 通过发行股份及支付现金方式购买澎立生物医药技术（上海）股份有限公司（以 下简称"澎立生物"或"标的公司"）100.00%股权（以下简称"本次发行股份及 支付现金购买资产"），并向不超过 35 名特定投资者发行股票募集配套资金（以 下简称"本次募集配套资金"，与本次发行股份及支付现金购买资产合称"本次 交易"）。 2025 年 12 ...

2026 年 1 月 上海市方达律师事务所 法律意见书 FANGDA PARTNERS 上海市方达律师事务所 关于上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套资金之 标的资产过户情况的 法律意见书 http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套资金之 标的资产过户情况的 法律意见书 致：上海奥浦迈生物科技股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法 律执业资格的律师事务所。根据上海奥浦迈生物科技股份有限公司（以下简称 "上市公司"或"奥 ...

国泰海通证券股份有限公司 关于 上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套资金 之 标的资产过户完成情况的 独立财务顾问核查意见 独立财务顾问 二〇二六年一月 声明 国泰海通证券股份有限公司（以下简称"国泰海通"、"独立财务顾问"） 受上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"、"上市公司"、"公 司"）委托，担任本次上海奥浦迈生物科技股份有限公司发行股份及支付现金购 买资产并募集配套资金之独立财务顾问，并出具本独立财务顾问核查意见。 本独立财务顾问核查意见系依照《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司重大资产重组管理办法》（以下简称"《重组管理办法》"）、《公开发行 证券的公司信息披露内容与格式准则第 26 号——上市公司重大资产重组》等法 律、法规的有关规定，按照证券行业公认的业务标准、道德规范和诚实信用、勤 勉尽责精神，遵循客观、公正的原则，在认真审阅相关资料和充分了解本次交易 行为的基础上编制而成。本独立财务顾问对本核查意见特作如下声明： 1、本独立财务顾问与本次交易各方当事人均无关联关系， ...

Group 1 - The company plans to acquire 100% equity of Pengli Bio through a combination of issuing shares and cash payment, along with raising supporting funds [1] - As of January 14, 2026, the equity transfer of Pengli Bio has been completed, with the company directly holding 374,808,585 shares, resulting in a 100% ownership stake [1] - Pengli Bio will become a wholly-owned subsidiary of the company and will be included in the consolidated financial statements [1] Group 2 - The company is required to pay the transaction price, raise supporting funds, and complete business registration changes as part of the acquisition process [1] - Intermediary institutions have confirmed that the transfer procedures for this transaction are legal and valid, with no substantial obstacles anticipated for subsequent matters [1]

Group 1 - Aopumai's stock price increased by 1.49% to 56.59 CNY per share, with a trading volume of 124 million CNY and a turnover rate of 1.91%, resulting in a total market capitalization of 6.441 billion CNY [1] - The stock has risen for five consecutive days, accumulating a total increase of 9.86% during this period [1] - Aopumai, established on November 27, 2013, and listed on September 2, 2022, specializes in cell culture products and services, with revenue composition of 87.34% from products, 12.53% from services, and 0.13% from other sources [1] Group 2 - The Qianhai Kaiyuan Fund holds Aopumai as a significant investment, with 58,600 shares representing 1.05% of the fund's net value, making it the sixth-largest holding [2] - The fund has realized a floating profit of approximately 48,600 CNY today and 297,500 CNY during the five-day increase [2] - The Qianhai Kaiyuan Fund, established on June 24, 2016, has a current size of 270 million CNY, with a year-to-date return of 1.59% and a one-year return of 16.5% [2]

Group 1: Market Dynamics - As of January 12, 2026, there were 19 new private placement projects added in the last two weeks, a decrease of 5 projects compared to the previous period[7] - The number of projects terminated increased by 1 to 6, with 2 being competitive bidding projects[7] - The approval rate for projects was 100%, with 11 projects approved by the review committee, an increase of 1[19] Group 2: Fundraising and Valuation - The total fundraising amount for the 4 projects listed in the last two weeks was 2.825 billion yuan, a decrease of 61.23%[34] - The average price discount rate for competitive bidding projects was 22.76%, an increase of 10.20 percentage points[34] - The PE and PB ratios for Dongfang Tantalum were 71.14x and 6.92x, respectively, significantly higher than the industry average[22] Group 3: Performance Metrics - The absolute return rate for newly unlocked competitive bidding projects averaged 60.55%, with an excess return rate of 26.36%, both up over 36 percentage points[4] - The average industry beta during the "issuance-unlocking" period was 43.76%, an increase of 14.97 percentage points[4] - The average individual stock alpha during the same period was 35.66%, up 29.54 percentage points[4] Group 4: Risk Factors - Potential risks include slower-than-expected approval processes, fluctuations in secondary market stock prices, and changes in the competitive bidding market environment[4]

证券日报网讯 1月9日，奥浦迈发布公告称，根据全国高新技术企业认定管理工作领导小组办公室发布 的《对上海市认定机构2025年认定报备的第一批高新技术企业进行备案的公告》，公司已通过高新技术 企业认定，同时，公司全资子公司上海奥浦迈生物工程有限公司亦通过了高新技术企业首次认定，证书 编号分别为：GR202531001853、GR202531002392，有效期为三年。 （文章来源：证券日报） ...

根据全国高新技术企业认定管理工作领导小组办公室发布的《对上海市认定 机构 2025 年认定报备的第一批高新技术企业进行备案的公告》，上海奥浦迈生物 科技股份有限公司（以下简称"奥浦迈"或"公司"）已通过高新技术企业认定， 同时，公司全资子公司上海奥浦迈生物工程有限公司（以下简称"奥浦迈生物工 程"）亦通过了高新技术企业首次认定，证书编号分别为：GR202531001853、 GR202531002392，有效期为三年。 根据《中华人民共和国企业所得税法》及国家对高新技术企业的相关税收政 策等有关规定，公司及全资子公司自本次通过高新技术企业认定当年起连续三个 会计年度可享受国家税收优惠政策，即按 15%的税率缴纳企业所得税。本次通过 高新技术企业认定事项，有助于进一步提高公司的核心竞争力，对公司的持续经 营和未来发展具有积极的作用。本次高新技术企业认定对公司财务状况的影响最 终以审计机构年度审计确认后的结果为准，敬请广大投资者注意投资风险。 特此公告。 上海奥浦迈生物科技股份有限公司董事会 2026 年 1 月 10 日 证券代码：688293 证券简称：奥浦迈 公告编号：2026-006 上海奥浦迈生物科技股 ...

格隆汇1月9日丨奥浦迈(688293.SH)公布，根据全国高新技术企业认定管理工作领导小组办公室发布的 《对上海市认定机构 2025 年认定报备的第一批高新技术企业进行备案的公告》，公司已通过高新技术 企业认定，同时，公司全资子公司上海奥浦迈生物工程有限公司亦通过了高新技术企业首次认定，证书 编号分别为：GR202531001853、GR202531002392，有效期为三年。 根据《中华人民共和国企业所得税法》及国家对高新技术企业的相关税收政策等有关规定，公司及全资 子公司自本次通过高新技术企业认定当年起连续三个会计年度可享受国家税收优惠政策，即按15%的税 率缴纳企业所得税。本次通过高新技术企业认定事项，有助于进一步提高公司的核心竞争力，对公司的 持续经营和未来发展具有积极的作用。 ...

Summary of Conference Call Records Industry Overview - The life sciences service sector, particularly the CXO segment, continues to experience high growth and is expected to deliver strong performance in 2026, benefiting from the upward cycle in innovative drugs and improved investment conditions [1][2][3] Key Companies and Performance - Notable companies in the life sciences service industry include: - **Hao Yuan Medicine**: Q3 revenue growth close to 30%, with a non-recurring profit growth of 70%. The company has secured orders exceeding 630 million yuan, a 50% year-on-year increase [2][8] - **Bai Ao Sai Tu**: Achieved a revenue growth of 60% in Q3 and recorded its first annual profit, with significant potential in humanized mouse sales and antibody business [2][8] - **WuXi AppTec**: Expected to see over 60% revenue growth in the ADC sector in the first half of 2026, with a strong order backlog [10][19] - **Kailai Ying**: Positioned well in the ADC market, with significant growth potential [10][19] - **Yangguang Nuohe**: Anticipated to achieve a profit of 300 million yuan in 2026, with a promising drug pipeline [20] Financial Performance - In the first three quarters of 2025, 16 representative life sciences service companies reported revenue and profit growth rates of high single digits and double digits, respectively. In Q3 alone, revenue and profit growth rates were double digits and 50%, indicating significant operational improvement [4][6] - The gross profit margin is expected to improve due to a clearer competitive landscape, leading to enhanced industry profitability [4] Market Trends - The overseas market is benefiting from improved investment conditions and the Federal Reserve's interest rate cuts, leading to an increase in the share of overseas business and expanding global market potential [7] - The domestic CRO market is experiencing a price recovery trend after years of intense competition, with expectations for more significant price improvements by 2027 as supply conditions stabilize [11][12] Growth Opportunities - The ADC and small nucleic acid sectors are projected to bring substantial order increases in 2026, with companies like WuXi AppTec and Hao Yuan Medicine expected to lead this growth [10][19] - The CRO sector is seeing a shift towards innovation, with companies like Yangguang Nuohe and Chengdu Xian Dao making progress in developing innovative drugs [13] Investment Recommendations - Recommended companies for investment include: - **WuXi AppTec**: Strong growth in peptide business and expected to achieve significant revenue increases [14][17] - **Kailai Ying**: Leading in peptide capacity expansion [14] - **Tigermed**: Positioned well in the CRO market with growth potential [21] - **Norseg and Prasis**: Expected to benefit from overall industry trends [17] Conclusion - The life sciences service industry is poised for continued growth, driven by innovative drug development, improved investment conditions, and a recovering market landscape. Key players are expected to deliver strong financial performance, making them attractive investment opportunities.